60mg tirzepatide vial 60mg/3mL (20mg/mL) Tirzepatide 60mg | GIP/GLP-1 Receptor

Individuals who have been diagnosed with ADHD since childhood may find that their medication has become less effective over time

Our mission: helping over 550,000 people transform their health starting with you

GLP-1 receptor agonists (Wegovy, Saxenda, and soon Zepbound/Mounjaro for obesity) are now covered by many commercial insurers, though usually with prior authorization requirements: Medicare is about to change the game entirely

Reinstate tirzepatide on the shortage list, allowing compounders to continue producing it under federal law

Its unique biological activity and stability have made it a valuable compound in studies focused on recovery, healing mechanisms, and overall tissue health

Adjuvant pharmacotherapies typically have demonstrated modest efficacy, and this may partly be due to physiological counter-regulatory mechanisms